

# **Pharmaceutical** and **Pharmacological** **Letters**

**Volume 2 1992/1993**

***Board of Editors:***

**P. Dominiak**, Lübeck, Germany

**V.J. Dzau**, Stanford, USA

**G. Franz**, Regensburg, Germany  
(Managing Editor)

**R. Gröning**, Münster, Germany

**H.-D. Höltje**, Berlin, Germany

**L. H. Hurley**, Austin, USA

**C. Melchiorre**, Bologna, Italy

**W.A. Ritschel**, Cincinnati, USA

**B. Testa**, Lausanne, Switzerland

**M. Tomoda**, Tokyo, Japan

**D.J. Triggle**, Buffalo, USA

**Y. Yamori**, Izumo, Japan



**Springer International**

## Contents of volume 2 1992/1993

No. 1: pp. 1–42 published May 1992  
No. 2: pp. 43–80 published June 1992  
No. 3: pp. 81–122 published August 1992  
No. 4: pp. 123–162 published October 1992  
No. 5: pp. 163–198 published December 1992  
No. 6: pp. 199–240 published February 1993

- Adler J → Barrett DA  
Allgaier C, Hertting G, Gottstein P:  
Muscarinic receptor-mediated regulation  
of electrically evoked acetylcholine  
release in hippocampus: effects of K<sup>+</sup>  
channel blockers 191  
Angeli P → Scapecchi S  
Angeli P, Brasili L, Gulini U,  
Cantalamesa F: Determination of  
muscarinic agonist potencies at M<sub>1</sub>  
and M<sub>2</sub> receptors in the pithed rat  
207  
Arai I → Murakami S  
Arakawa R → Uchida M  
Arbogast H → Nees S  
Baba K → Murakami S  
Balansard G → Ollivier E  
Ball B → Dominiak P  
Barrett DA, Adler J, Nickalls RWD,  
Shaw PN: Microdialysis sampling in  
vitro: the effect on recovery of probe  
length, flow rate and temperature  
139  
Bartel S → Tenor H  
Bauer KH → Sarlikiotis AW  
Beblo S → Becker BF  
Becker BF, Zahler S, Raschke P,  
Schwartz LM, Beblo S: Adenosine  
enhances neutrophil sticking in the  
coronary system: a novel mechanism  
contributing to cardiac reperfusion  
damage 8  
Becker BF, Dominiak P, Schrader J,  
Zimmer H-G: Preface 1  
Behl CR → Kislalioglu MS  
Bejeuhr G, Holzgrabe U, Mohr K,  
Sürig U, Petersenn A von: Molecular  
modelling and synthesis of potent  
stabilizers of antagonist binding to  
M-cholinoceptors 100  
Betzing J → Sarlikiotis AW  
Bhalla DV, Kulkarni VM: A three-  
component pharmacophore for  
sulphonylurea receptor ligands 163  
Bhatnagar R, Ritschel WA: Pharmacokinetics  
of dihydrotetabenazine after  
intravenous and peroral administration  
to rats 89  
Bhatnagar R, Ritschel WA: Transdermal  
feasibility studies of dihydrotetabenazine  
in rats 92  
Birker B → Rose H  
Blagbrough IS, Daykin MM,  
Doherty M, Patrick M, Shaw PN:  
Plasma and synovial fluid pharmacokinetics  
of naproxen in osteo- and  
rheumatoid arthritis in patients:  
relationship to clinical response 70  
Blöchl A → Dominiak P  
Brasili L → Angeli P  
Bries D → Kinget R  
Brune K → Nuernberg B  
Brunet C → Cabanis A  
Budd K → Janicki PK  
Bünger R → Mukohara N  
Bünning P → Gohlke P  
Cabanis A, Gressier B, Lebegue S,  
Dine T, Brunet C, Luyckx M,  
Cazin M, Cazin JC: Effects in vitro of  
mesna on the production of some  
reactive oxygen species by human  
neutrophils 236  
Cacini W → Zhan J  
Cagnotto A → Claudi F  
Canossa M, Ferri S, Romualdi P,  
Melchiorre C: Binding profile of WB  
4101, benoxathian and of their respective  
enantiomers at  $\alpha_1$ -adrenoceptor  
subtypes 77  
Cantalamesa F → Angeli P  
Capek P → Nosál'ová G  
Catarzi D → Colotta V  
Cateni F → Falsone G  
Cazin JC → Cabanis A  
Cazin M → Cabanis A  
Cecchi L → Colotta V  
Cingolani GM → Claudi F  
Claudi F, Cingolani GM, Di Stefano A,  
Giorgioni G, Cagnotto A, Skorupska  
M: Synthesis and evaluation of  
N-n-propyl-N-(2-phenylethyl)-2-(3-  
fluoro-4-hydroxyphenyl)ethylamine  
derivatives as dopamine  
receptor ligands 157  
Colotta V, Cecchi L, Catarzi D,  
Melani F, Filacchioni G, Martini C,  
Tacchi P, Lucacchini A: 1-(3-Amino-  
phenyl)-3-methyl[1]benzopyrano-  
[2,3-c]pyrazol-4-one: a new selective  
A<sub>2</sub> adenosine receptor antagonist 74  
Comte J-H → Debord J  
Crespin F → Ollivier E  
Dammer U → Nees S  
Daniels R, Mittermaier EM: Use of a  
streaming current detector to characterize  
the complex coacervation of  
gelatin and acacia 123  
Dannhardt G, Schneider G, Schwel B:  
Identification and 5-lipoxygenase  
inhibiting potency of medicarpin  
isolated from roots of *Ononis spinosa*  
L. 161  
Daykin MM → Blagbrough IS  
Debord J, Comte J-H, Lachatre G:  
Partial characterization of a carboxyl-  
esterase from guinea pig kidney 166  
Dei S → Scapecchi S  
Dendorfer A → Nees S  
Deuticke B: Membrane leakiness  
induced by oxidative damage:  
involvement of changes of membrane  
dielectric properties? 28  
Di Stefano A → Claudi F  
Diaz Lanza AM → Ollivier E  
Dine T → Cabanis A  
Dirsch V, Wiemann W, Wagner H:  
Antiinflammatory activity of  
triterpene quinone-methides and  
proanthocyanidins from the stem bark  
of *Heisteria pallida* Engl. 184  
Doherty M → Blagbrough IS  
Dominiak P, Blöchl A, Ball B: Actions  
of converting enzyme inhibitors on  
liver mitochondria of spontaneously  
hypertensive rats (SHR) 20  
Dominiak P → Becker BF  
Dubey NK → Mishra AK  
Duhm J, Engelmann B: Na<sup>+</sup>-Li<sup>+</sup>  
countertransport of erythrocytes and  
cardiovascular pathophysiology: the  
lipid hypothesis 32  
Egawa Y → Suzuki I  
Egawa Y → Yadomae T  
El-Alali A → Falsone G  
Elias-Jones AC, Larcher VF, Shaw PN:  
An investigation into the relationship  
between liver impairment and  
theophylline pharmacokinetics in  
children 115  
Elias R → Ollivier E  
Engelmann B → Duhm J  
Erskine WAR → Janicki PK  
Falsone G, Cateni F, El-Alali A,  
Papaioannou A, Ravalico L,  
Furlani A: Synthesis of  $\alpha$ -chrysan-  
themoylmethylen-isatin and  $\gamma$ -  
lactones with cytostatic activity 104  
Fassihi RA → Ritschel WA  
Feil F, Tegtmeier M, Hahnemann B,  
Legrum W: Interactions of coumarin-  
metabolizing cytochrome P 450  
isozymes with analogues of umbelli-  
ferone 43  
Ferri S → Canossa M  
Fetzer J, Folkers G: Temperature  
dependent formation of inclusion  
bodies during the expression of  
recombinant viral thymidine kinase  
112  
Filacchioni G → Colotta V  
Fischer Y → Rose H  
Fleischer J, Moll F: In vitro evaluation  
of drug release from powders 143  
Folkers G → Fetzer J  
Frick A: Microperfusion studies in the  
inner medullary collecting duct in the  
isolated papilla of the rat kidney:  
evidence for an uptake of SO<sub>4</sub><sup>35</sup> 40  
Furlani A → Falsone G  
Gerhäuser C, Leonhardt K, Tan GT,  
Pezzuto JM, Wagner H: What is the  
active antiviral principle of *Thuja*  
*occidentalis* L.? 127  
Giorgioni G → Claudi F  
Gohlke P, Unger T, Bünning P:

- Distribution of the angiotensin converting enzyme inhibitor ramiprilat in the blood vessel wall 66
- Gohlke P → Metsärinne KP
- Gonda R, Tomoda M, Takada K: The core structure and immunological activities of ukonan B, the representative polysaccharide from turmeric, and its degradation products 50
- Gottstein P → Allgaier C
- Gressier B → Cabanis A
- Grobecker H → Raasch W
- Gualtieri F → Scapecchi S
- Gulini U → Angeli P
- Hahnemann B → Feil F
- Hamada H, Nakazawa K, Williams HJ, Scott AI: A significant increase in vindoline content of leaves of *Catharanthus roseus* is induced by UV light irradiation 218
- Hartmann RW: Development of a post-menopausal rat mammary tumor model 146
- Hasler A, Meier B: Determination of terpenes from *Ginkgo biloba* L. by capillary gas chromatography 187
- Herbots H → Kinget R
- Hertting G → Allgaier C
- Hiltunen R → Sevón N
- Holzgrabe U → Bejeuhr G
- Honda H → Uchida M
- Ionescu I → Rose H
- Janicki PK, Erskine WAR, Budd K: Differences in opioid fractional receptor occupancy (FRO) for morphine and morphine-6-glucuronide (M6G) in isolated guinea-pig ileum (GPI) in normal and morphine-tolerant animals 199
- Kaempfel U, Liefländer M: Polysaccharide covalently linked to the rigid layer of the cyanobacterium *Anabaena variabilis* ATCC 29413 224
- Kammermeier H → Rose H
- Kang YH → Mukohara N
- Kardošová A → Nosál'ová G
- Kawakita T → Suzuki I
- Kawakita T → Yadomae T
- Kees F → Raasch W
- Kikuchi S → Suzuki I
- Kikuchi S → Yadomae T
- Kinget R, Peeters R, Herbots H, Bries D: Amylose triacetate as an excipient for matrix tablets. I. In vitro study 210
- Kislalioglu MS, Sethi PK, Malick AW, Behl CR: In vitro iontophoretic permeation of a weak base erythromycin from different buffer solutions using hairless mouse skin 85
- Kozawa M → Murakami S
- Krause E-G → Tenor H
- Kulkarni VM → Bhalla DV
- Lachatre G → Debord J
- Larcher VF → Elias-Jones AC
- Lebegue S → Cabanis A
- Legrum W → Feil F
- Lehr M: In-vitro assay for the evaluation of phospholipase A<sub>2</sub> inhibitors using bovine platelets and HPLC with UV-detection 176
- Leonhardt K → Gerhäuser C
- Liefländer M → Kaempfel U
- Lucacchini A → Colotta V
- Luyckx M → Cabanis A
- Maillard C → Ollivier E
- Malick AW → Kislalioglu MS
- Marchetti NT → Pazur JH
- Martini C → Colotta V
- Marucci G → Scapecchi S
- Meier B → Hasler A
- Meier-Ewert H → Nees S
- Melani F → Colotta V
- Melchiorre C → Canossa M
- Metsärinne KP, Stoll M, Gohlke P, Paul M, Unger T: Angiotensin II is antiproliferative for coronary endothelial cells in vitro 150
- Mishra AK, Dubey NK, Mishra L: A fungitoxic principle from the leaves of *Prunus persica* 203
- Mishra L → Mishra AK
- Mishra Y, Ramzan I: Influence of cimetidine and ranitidine on gallamine disposition and neuromuscular pharmacodynamics in rats 169
- Miskiel FJ → Pazur JH
- Mittermaier EM → Daniels R
- Miura O → Yadomae T
- Mohr K → Bejeuhr G
- Moll F → Fleischer J
- Müller-Goymann CC → Rades T
- Mukohara N, Kang YH, Bünger R: Magnesium-induced coronary dilation and adenosine.  $\alpha$ ,  $\beta$ -methylene adenosine 5'-diphosphate attenuation and theophylline paradox 12
- Murakami S, Arai I, Muramatsu M, Otomo S, Baba K, Kozawa M: Daphnodorins inhibit gastric H<sup>+</sup>, K<sup>+</sup>-ATPase and acid secretion 108
- Muramatsu M → Murakami S
- Nagi N → Suzuki I
- Nakazawa K → Hadama H
- Nees S, Dendorfer A, Meier-Ewert H, Strohmer R, Stiegler H, Arbogast H, Dammer U, Schönharting M: Inhibition of PAF-induced aggregation of human PMNs and platelets by adenosine: in vitro investigations using a newly developed blood filtration system 36
- Nickalls RWD → Barrett DA
- Nomoto K → Suzuki I
- Nomoto K → Yadomae T
- Nosál'ová G, Strapková A, Capek P, Kardošová A: Antitussive activity of an  $\alpha$ -D-glucan isolated from the roots of *Althaea officinalis* L., var. *robusta* 195
- Nuernberg B, Schneider HT, Brune K: Biliary excretion of salicylates in man 135
- Ohno N → Yadomae T
- Oksman-Caldentey K-M → Sevón N
- Okunishi H: Prolonged and tissue-selective inhibition of vascular angiotensin-converting enzyme by trandolapril: relevance to its antihypertensive action in spontaneously hypertensive rats 180
- Ollivier E, Elias R, Maillard C, Diaz Lanza AM, Crespin F, Balansard G: Biotransformation of polyphenols in *Hamamelis virginiana* leaves according to the solvent used for the extraction 119
- Olsson RA: A brief history of adenosine research 3
- Otomo S → Murakami S
- Papaioannou A → Falsone G
- Patrick M → Blagbrough IS
- Paul M → Metsärinne KP
- Pazur JH, Miskiel FJ, Marchetti NT, Shiels HR: Sets of isomeric antibodies with specificity for the  $\alpha$ - and  $\beta$ -D-glucose units of glycoconjugates 232
- Petersenn A von → Bejeuhr G
- Peeters R → Kinget R
- Pezuto JM → Gerhäuser C
- Pöpping S → Rose H
- Raasch W, Grobecker H, Kees F: Influence of ciprofloxacin on brain metabolism of biogenic amines in the rat 153
- Rades T, Müller-Goymann CC: Structural investigations on the liquid crystalline phases of fenpropfen 131
- Ramzan I → Mishra Y
- Rao SS, Ritschel WA: Development and in vitro/in vivo evaluation of a transdermal drug delivery system of vasopressin 81
- Raschke P → Becker BF
- Ravalico L → Falsone G
- Ritschel WA, Vachharajani NN, Fassihi RA: In vitro model optimization for antacid evaluation based on physiological constraints and human gastric pH 58
- Ritschel WA → Bhatnagar R
- Ritschel WA → Rao SS
- Ritschel WA → Zhan J
- Romanelli MN → Scapecchi S
- Romualdi P → Canossa M
- Rose H, Birker B, Ionescu I, Pöpping S, Fischer Y, Kammermeier H: Negative inotropic effects of volatile anaesthetics and antiarrhythmic drugs in cardiomyocytes: analysis of contraction and energetics 16
- Sarlikiotis AW, Betzing J, Wohlschlegel C, Bauer KH: A new in-vitro method for testing colon targeting drug delivery systems or excipients 62
- Scapecchi S, Angeli P, Dei S, Gualtieri F, Marucci G, Romanelli MN, Teodori E: N,N-diethylaminoethanol and N-methyl-4-piperidinol esters of 2,2-diphenyl-2-ethylthioacetic acid as potent and selective muscarinic antagonists 220
- Schneider G → Dannhardt G
- Schneider HT → Nuernberg B

- Schönharting M → Nees S  
 Schrader J: Regulation of coronary blood flow by adenosine 5  
 Schrader J → Becker BF  
 Schwartz LM → Becker BF  
 Schwell B → Dannhardt G  
 Scott AI → Hamada H  
 Sethi PK → Kislalioglu MS  
 Sevón N, Hiltunen R, Oksman-Caldentey K-M: Chitosan increases hyoscyamine content in hairy root cultures of *Hyoscyamus muticus* 96  
 Shaw PN → Barrett DA  
 Shaw PN → Blagbrough IS  
 Shaw PN → Elias-Jones AC  
 Shiels HR → Pazur JH  
 Skorupska M → Claudi F  
 Stiegler H → Nees S  
 Stoll M → Metsärinne KP  
 Strapková A → Nosál'ová G  
 Strohmenger R → Nees S  
 Sürig U → Bejeuhr G  
 Suzuki I, Egawa Y, Nagi N, Yasuzawa Y, Yadomae T, Kawakita T, Kikuchi S, Nomoto K: Effects of chinese herbal medicines, saikozai, on antibody response and macrophage activities 214  
 Suzuki I → Yadomae T  
 Tacchi P → Colotta V  
 Takada K → Gonda R  
 Tan GT → Gerhäuser C  
 Tegtmeier M → Feil F  
 Tenor H, Bartel S, Krause E-G: Trapidil, a triazolopyrimidine, competes only moderately with A<sub>1</sub>-adenosine receptor binding sites from brain and heart 47  
 Teodori E → Scapecchi S  
 Tomoda M → Gonda R  
 Uchida M, Arakawa R, Honda H: Effects of ambroxol HCl on pulmonary surfactant secretion in normal and reserpinized rats 173  
 Unger T → Gohlke P  
 Unger T → Metsärinne KP  
 Vachharajani NN → Ritschel WA  
 Wagner H → Dirsch V  
 Wagner H → Gerhäuser C  
 Wiemann W → Dirsch V  
 Williams HJ → Hamada H  
 Wohlschlegel C → Sarlikiotis AW  
 Yadomae T, Suzuki I, Yasuzawa Y, Egawa Y, Ohno N, Kawakita T, Kikuchi S, Miura O, Nomoto K: Effect of a traditional herbal medicine, jia-wei-gui-pi-tang (japanese name: kami-kihi-to) on the antibody responses in mice 228  
 Yadomae T → Suzuki I  
 Yasuzawa Y → Suzuki I  
 Yasuzawa Y → Yadomae T  
 Zahler S → Becker BF  
 Zhan J, Ritschel WA, Cacini W: Relation of disposition kinetics to anxiolytic effect of intraperitoneal administration of carbamazepine in rats 54  
 Zierhut W, Zimmer H-G: Effects of angiotensin converting enzyme inhibition on triiodothyronine-induced cardiac hypertrophy in rats 24  
 Zimmer H-G → Becker BF  
 Zimmer H-G → Zierhut W

## Inhibition of PAF-induced aggregation of human PMNs and platelets by adenosine: in vitro investigations using a newly developed blood filtration system

S. Nees<sup>1</sup>, A. Dendorfer<sup>1</sup>, H. Meier-Ewert<sup>1</sup>, R. Strohmenger<sup>1</sup>, H. Stiegler<sup>2</sup>, H. Arbogast<sup>2</sup>, U. Dammer<sup>2</sup>, and M. Schönharting<sup>3</sup>

<sup>1</sup>Physiologisches Institut der Universität München, Pettenkoferstrasse 12, W-8000 München 2,

<sup>2</sup>Chirurgische Klinik Klinikum Großhadern der Universität München, Marchioninistrasse 15, W-8000 München 70,

<sup>3</sup>Hoechst AG Werk Kalle-Albert, Klinische Forschung, Postfach 3540, W-6200 Wiesbaden 1, Federal Republic of Germany

Received 3 April 1992

**Abstract.** An innovative filtration system permits the quantitative study of humoral and cellular interactions in flowing blood under the influence of mediators and inhibitors of inflammation. In an initial study it could be demonstrated in diluted human whole blood that PAF rapidly induced plugging of capillary-sized pores due to changes in shape and adhesivity of the PMNs and platelets. Adenosine proved to be a potent inhibitor. This nucleoside is increasingly produced in PAF-stimulated and filtrated blood, especially after its contact with cultured endothelial cells. In conclusion, these observations contribute to explain why, in the centre of a focus of inflammation *in vivo*, perfusion ceases while hyperaemia occurs in the adjacent marginal zone.

### Abbreviations


PAF: platelet activating factor, FMLP: N-formyl-L-methionyl-L-leucyl-L-phenylalanine, PMN: polymorphonuclear leukocytes, EHNA: erythro-9-(2-hydroxy-3-nonyl) adenine, CAD: coronary artery disease.

### Introduction

Although many new insights into the interactions between blood cells and the vascular wall in inflamed areas have been obtained through the systematic use of modern immunological and microscopical techniques, many unanswered questions remain, the resolution of which requires special *in vitro* methods that have yet to be developed. For example, it is not known to which extent the reorganisation of inherent leukocytic membrane structures or the formation of new ones induced by mediators of inflammation might modify the rheological behaviour of whole blood. A prompt enhancement of the adhesivity or a reduction in the deformability of the

PMNs brought about in this way could, in particular in the early stage of inflammation, contribute greatly towards initiating the interaction of these cells with the cell adhesion molecules [1] of the stimulated endothelium. Also, not very much is known about the role played by the platelets or blood plasma in the early stages of the inflammatory process. Moreover, until today a phenomenon could not be explained that has been known to pathologists since the time of R. Virchow, namely, while in the centre of a focus of inflammation perfusion ceases, hyperaemia develops in the adjacent marginal zone.

Evidence is, however, accumulating to suggest that the complex cellular reactions and interactions in the vascular bed depend not only on numerous soluble activators, but also on inhibitors, and that it is the concerted action of all these various influences on all the blood cells and the vascular endothelium that decides whether the vessels in an organ will be perfused physio-



**Fig. 1.** Schematic diagram of the filtration system. 1: gas cylinder, 2: electronically regulated pressure device, 3: filtration chamber, 4: whole blood, 5: filter (thickness: 10  $\mu\text{m}$ , pore diameter: 5  $\mu\text{m}$ ), 6: filtrate detector, 7: computer and plotter

logically, or whether a thrombotic or inflammatory process will develop [2].


Unfortunately, accurate biochemical research into these interrelationships under *in vivo* conditions is limited by almost insurmountable methodological shortcomings. However, using a specially developed, versatile blood filtration system, we can now quantitatively measure the cell-specific effects and concentration-dependent actions of blood cell activators or inhibitors in flowing whole blood under largely defined *in vitro* conditions. This is described below for a) PAF, a typical inflammation mediator [3], and for b) adenosine which is liberated from the endothelial lining of blood vessels or produced there by extracellular degradation of adenine nucleotides [4].

## Methods

Venous blood was freshly drawn from healthy donors, anticoagulated with citrate, and stored in stoppered and slowly rotated polyethylene tubes at 37°C until used. Prior to filtration, the blood samples were always diluted to a haematocrit of 6% with a physiologically balanced salt solution, and mixed with heparin (9 IU/ml).

Platelet-rich plasma was obtained by centrifugation of citrated blood (10 min at 1,500 rpm, Labofuge, Christ). PMNs were purified (95%) with the aid of defined Nycodenz solutions in accordance with the instructions of the manufacturer (Nycomed, Torshov, Norway).

The schematic diagram of the blood filtration system (recently developed in cooperation with the company of BOSCH-Wägetechnik GmbH, D-7455 Jungingen) is shown in Fig. 1. The blood cells were filtered through a polycarbonate filter (Nucleopore, Pleasanton, Calif.;




**Fig. 2.** Principle of the quantitative evaluation of the filtration data. Time courses of filtrate accumulation and filtration rate: curves 1 and 2, respectively; evaluation interval: 3; tangent: 4. A few seconds after the onset of filtration, the process is characterized by a phase in which a practically constant fraction of the filter pores is being plugged by PMNs and/or platelets per unit of time. The duration of this phase primarily depends upon the rapidity of activation of these cells, and the corresponding flow  $F$  through the filter can be described by the relationship  $F = \alpha \cdot e^{-\beta t}$  ( $\alpha$ : material constant of the filter;  $\beta$ : plugging rate;  $t$ : filtration time).  $\beta$  is determined by the slope of the tangent (a/b) drawn to curve 2. Occlusion rate =  $(1 - e^{-\beta t}) \times 100$  [%/s]

thickness 10  $\mu\text{m}$ , pore diameter 5  $\mu\text{m}$ ) in a pressure gradient (12 cm  $\text{H}_2\text{O}$ ) kept constant by electronic means. The amount of filtrate was continuously determined gravimetrically with the aid of an electronic detector, and the results fed on-line to a computer and evaluated in accordance with the principle shown in Fig. 2.

After performance of the experiments, the filters were removed immediately, fixed and histochemically investigated. The influence of umbilical vein endothelial cells on the production of adenosine was investigated by passing PAF-stimulated blood samples through columns ( $\varnothing$ : 5 mm, length: 2 cm) packed with microbeads (Biosilone, Nunc, Roskilde, Denmark) on which confluent layers of this endothelial cell type had been established [5]. Adenosine was analysed according to HPLC-standard procedures [6].

## Results

Under largely physiological conditions (constant pressure gradients, 37°C, 1.2 mM  $\text{CaCl}_2$ ), heparinized whole blood readily passed through the capillary-sized pores of the measuring system at an almost constant, high flow rate (occlusion rate =  $1.3 \pm 0.32$  %/s,  $n = 18$ ). After preincubation with PAF, in contrast, the pores became progressively blocked. The calculated occlusion rate revealed a characteristic concentration dependence (Fig. 3). Analogous studies performed with purified sus-



**Fig. 3.** Dose effect curves of PAF on the occlusion rate during filtration of whole blood, purified PMNs, or platelet rich plasma, respectively (details see text).  $n = 5$ , means  $\pm$  SD. A significant increase in the occlusion rate during filtration of whole blood occurred already at a PAF-concentration of 2 nM ( $p = 0.05$ )

pensions of various blood cell types, the respective concentrations of which were adjusted to those found in correspondingly diluted whole blood, showed that the microrheological behaviour of the RBCs or lymphocytes was not influenced by PAF. In contrast, purified PMNs and platelets both occluded the filter pores in the presence of PAF, and the resulting dose-effect curves, taken together, could explain the curve obtained for whole blood in good approximation. Staining and microscopic examination of the filters finally proved




Fig. 4. Scanning electron micrographs of filters through which whole blood has been passed for 30 s in the presence of a) 2 nM, b) 200 nM PAF, and c) in the absence of PAF

that, in whole blood, PAF selectively stimulates only the PMNs and the platelets. During this process, these two cell species changed shape in a typical manner. On the basis of the  $EC_{50}$  values given in Fig. 3, it can be seen that PMNs are stimulated by appreciably lower concentrations of PAF than the platelets. Furthermore, under the influence of PAF, PMNs and platelets in whole blood interacted, and it were the resulting micro-coaggregates that finally plugged the capillary pores (Fig. 4a and b). The specificity of these interactions was underscored by the fact that in the absence of PAF, no cell aggregates were to be detected on the surface and in the pores of the biologically inert filters (Fig. 4c).




Fig. 5. Inhibition of occlusion rate induced by PAF ( $0.05 \mu\text{M}$ ) by various concentrations of adenosine or 5'-AMP. Blood samples were preincubated for 90 s with the respective inhibitor, and for 60 s with PAF.  $n=5$ , means  $\pm$  SD. A highly significant decrease in the occlusion rate occurred already at  $10^{-7}$  M adenosine and  $10^{-6}$  M AMP, respectively ( $p = 0.01$ )

Adenosine appreciably suppressed the negative effect of PAF on the microrheological properties of whole blood, already at physiological plasma concentrations (approx.  $2 \times 10^{-7}$  M), and even completely prevented it at higher concentrations (Fig. 5). 5'-AMP developed an appreciable inhibitory effect only at much higher concentrations. With the aid of sensitive HPLC techniques this "AMP-effect" could be traced back solely to adenosine, which was formed from 5'-AMP by the action of 5'-nucleotidase present on the cell membrane of lymphocytes and monocytes. Inosine proved to be completely inert.

As Fig. 6 reveals, the plasma adenosine concen-




Fig. 6. Plasma adenosine concentration in (1) whole blood (mixed with  $10 \mu\text{M}$  dipyridamol and  $10 \mu\text{M}$  EHNA) in the absence of PAF (a) prior, b) 1 min after filtration and immediate centrifugation (endothelial cells had no influence on these values); (2a,b) as in (1), but in the presence of PAF ( $1 \mu\text{M}$ ); (3) as in (2b), but after subsequent passage during 1 min through a microcarrier column coated with endothelial cells.  $n=4$ , means  $\pm$  SD

tration of whole blood was unaffected by the filtration process, since the values prior and after passage of the pores were identical. However, blood samples which were stimulated with PAF contained appreciably higher adenosine concentrations after passage of the pores than before, due to stimulated release and degradation of adenine nucleotides from the platelets. Interestingly, if these samples were subsequently passaged through densely packed endothelial cell cultures, the adenosine concentration was further elevated. As relevant control experiments reveal, approximately 20% of this nucleoside fraction was released from the endothelial cells.

## Discussion

Filtration techniques have been in use for some time to characterise the passive rheological behaviour of blood, mainly in the form of purified RBC suspensions [7]. However, for a reliable recording of active and rapid  $\text{Ca}^{2+}$ -dependent leukocyte and platelet reactions and interactions at a temperature of 37°C, the measuring devices and evaluation procedures described in the literature are not adequate. This technical limitation has now been overcome by the sensitive, electronically controlled filtration procedure we have developed. The haematocrit of 6% we selected is of the order of magnitude of microhaematocrit values measured *in vivo* [8].

Scanning electron microscopic examinations revealed that PAF can stimulate PMNs and platelets to effect highly complex changes in their shape, size, rigidity, adhesivity, and aggregability. As we have demonstrated, these effects occurred statistically significant even at low PAF concentrations around 2 nM. Such values can be found in arterial blood of CAD-patients [9], and are probably even higher in blood under conditions of septicaemia.

In other studies [10], we have been able to show that FMLP, another mediator of acute inflammation, selectively activated the PMNs in whole blood, while 5'-ADP stimulated only the platelets. However, in these cases, too - probably mediated by products (e.g. oxygen radicals) released secondarily by the stimulated cells - activation of the respective other cell species soon occurred. This close cooperation between PMNs and platelets has to date received but little attention in studies of inflammatory processes.

*In vivo* the concentration of PAF is greatest at the centre of an inflammatory focus due to its release from activated leukocytes and endothelial cells [3]. The moment PAF accumulates in the microcirculation of the inflamed area, it should rapidly induce similar cellular reactions as we could demonstrate *in vitro*. The resulting plugging of the capillaries by the blood cells and the decrease of flow are then probably very important preconditions for the PMNs and monocytes to attach to the vascular wall and to bind to the initially only weakly ex-

pressed adhesion molecules at the endothelium [1].

The PAF-activated platelets, on the other hand, release ADP and ATP, which can be dephosphorylated to adenosine in the intravascular space, but rapidly only by the luminal ecto-nucleotidases of the vascular endothelium. As the blood is distributed within more and more microvessels downstream of the focus of inflammation, it is simultaneously being brought into contact with an ever increasing endothelial surface. In this way, it would be possible *in vivo* for considerable concentrations of adenosine to build up in the very surrounding of the primary focus. Together with other typical endothelial cell release products, such as prostanoids ( $\text{PGI}_2$ ,  $\text{PGE}_1$ ,  $\text{PGE}_2$ ) and nitric oxide (NO) this could prevent PMNs and platelets from entering the remaining circulation in an activated state. All these compounds are potent vasodilators, and might thus also be responsible for the hyperaemia that is typically observed in the marginal zone surrounding the focus of an inflammation.

Finally, mediators of acute inflammation, like PAF [3], and endothelium-derived inhibitors of leukocytes and platelets, like adenosine [6], have only a short half-life in circulating blood. This could contribute to explain why, immediately outside the zone of inflammation, physiological perfusion and regulation of the blood vessels are again observed.

*Acknowledgements.* We would like to acknowledge the valuable technical assistance of Mrs. Schaefer-Grunitz and the indispensable secretarial work of Mrs. Schaipp-Metzner in the preparation of this manuscript.

## References

- Osborn L (1990) *Cell* 62:3-6
- Gerlach E, Becker BF (1990) In: Bleifeld W, Hamm CW, Braunwald E (eds) Springer Verlag, Berlin Heidelberg, pp 3-15
- Braquet P, Touquill L, Shen TY, Vargaftib BB (1987) *Pharmacol Rev* 39:97-145
- Gerlach E, Becker BF, Nees S (1987) In: Gerlach E, Becker BF (eds) Springer Verlag, Berlin Heidelberg, pp 309-320
- Jaffe EA, Nachman RL, Becker CG, Minick CR (1973) *J Clin Invest* 52:2745-2756
- Möser GH, Schrader J, Deussen A (1989) *Am J Physiol* 256: C799-806
- Hanss M (1983) *Biorheology* 20:199-211
- Lipowsky HH, Usami S, Chien S (1980) *Microvasc Res* 19:297-319
- Montrucchio G, Camussi G, Tetta C, Emanuelli G, Orzan F, Libero L, Brusca A (1986) *Lancet* Vol. II: 293
- Nees S, Dendorfer A (1991) In: Inoue M, Hori M, Imai S, Berne RM (eds) Springer Berlin Heidelberg, pp 169-178